Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Three Patent Applications Related to RNAi: May 17, 2007

Premium
Title: Bioinformatically Detectable Group of Novel HIV Regulatory Genes and Uses Thereof
 
Numbers: 7,217,807
 
Filed: Aug. 28, 2003
 
Inventor: Isaac Bentwich, Rosetta Genomics
 
The patent, its abstract states, relates to “a group of novel viral RNA regulatory genes, here identified as viral genomic address messenger genes or VGAM genes, and … genomic record or GR genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease,” the abstract states. “Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.”
 

 
Title: Gene Expression Suppression Agents
 
Numbers: 20070105795
 
Filed: May 12, 2003 PCT Filed: May 12, 2003
 
Lead Inventor: Yingxian Xiao, Potomac Pharmaceuticals
 
According to the patent application’s abstract, the invention comprises “a method … for making gene suppression agents to be used in eukaryotic cells by using a recombinant DNA construct containing at least one transcriptional unit compromising a transcriptional promoter, a template sequence for making a RNA molecule, and a transcriptional terminator. Mechanisms of the RNA mediated gene suppression include, but [are] not limited to, RNA interferences. The use of the agents as tools for biomedical research as well as medicinal products is also disclosed,” the abstract adds.
 

 
Title: Methods of Degrading dsRNA and Synthesizing RNA
 
Numbers: 20070105113
 
Filed: Aug. 10, 2004 PCT Filed: Aug. 10, 2004
 
Lead Inventor: Hiroaki Sagawa, Takara Bio
 
The patent application, it’s abstract states, claims “a protein having an activity of degrading a dsRNA, namely, being capable of acting on a long-chain dsRNA to form a dsRNA of a definite length; a method of efficiently preparing a dsRNA of a definite length which comprises treating a dsRNA with the protein having an activity of degrading a dsRNA in the coexistence of a protein having an activity of binding to a nucleic acid such as a protein having an RNA-binding activity; and a method of using the protein having an activity of binding to a nucleic acid to elevate the efficiency in an RNA synthesis reaction typified by dsRNA synthesis.”
 

 
Title: Small Interfering RNA-Mediated Transcriptional Gene Silencing in Mammalian Cells
 
Numbers: 20070104688
 
Filed: May 24, 2006
 
Lead Inventor: John Rossi, City of Hope
 
The invention, the patent application’s abstract states, “relates to transcriptional gene silencing in mammalian, including human, cells that [are] mediated by small interfering RNA molecules. The present invention also relates to a method for directing histone and/or DNA methylation in mammalian, including human, cells. It has been found that siRNAs can be used to direct methylation of DNA in mammalian, including human, cells.”

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.